Cardiovascular Alterations associated with Interleukin-2 Therapy

摘要: Renal cell carcinoma affects approximately 28000 patients per year in the United States. The prognosis of with this malignancy is poor a 5-year survival 15% metastatic disease. Two major characteristics disease contribute to low survival. First, usually present advanced because lack early clinical symptoms and cost effective screening tests. Second, neoplasia possesses innate resistance conventional chemotherapeutic agents. Interleukin-2 (IL-2) among most active agents for treatment disseminated renal carcinoma. antitumor activity against was first reported during early, phase I studies at National Institute Health [1]. Subsequent trials confirmed IL-2 which lead approval by U.S. Food Drug Administration kidney cancer. Approval based on finding that significant, durable responses were observed (17-33%) some cured their (approximately 5%).